Director Eldora L. Ellison, Ph.D. was quoted in the article “USPTO Faces Growing Pressure To Enter Battle Over Drug Pricing,” published by Pink Sheet. She comments on the pharmaceutical patent petitioner viewpoint regarding the increase in discretionary denials of IPR petitions at the PTAB. From the article:

“Attorneys specializing in IPR cases have differing views on whether the uptick in discretionary denials is a negative development.

‘Amongst the patent bar and stakeholders this is a significant issue,’ Eldora Ellison, co-chair of Sterne Kessler Goldstein & Fox’s patent office litigation practice, said. ‘For petitioners, there is concern as to what they’d say is the unpredictability’ of whether a trial will be instituted on their petition.”